Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Recent Alzheimer's disease dynamics are a positive for Biogen's Leqembi - Oppenheimer

Published 03/11/2024, 02:01 PM
Updated 03/11/2024, 02:04 PM
© Reuters.  Recent Alzheimer's disease dynamics are a positive for Biogen's Leqembi - analyst
BIIB
-

On Monday, Oppenheimer reiterated its Outperform rating and $290 price target for Biogen (NASDAQ:BIIB) amid recent developments in the Alzheimer's Disease (AD) treatment landscape. The competitive dynamics have shifted significantly, potentially benefiting Biogen's AD drug, Leqembi, which is developed in partnership with Eisai. Eisai has reported progress on multiple fronts for Leqembi, while a competitor, Eli Lilly (NYSE:LLY), announced an unexpected delay for its AD drug, donanemab, due to a pending FDA Advisory Committee (Ad Comm) meeting.

Eisai's update highlighted several growth drivers for Leqembi, including a 30% increase in Neurology Account Specialists, expanded dosing options, broader use of blood-based biomarkers, enabling Primary Care Physicians to prescribe the drug, targeting a larger patient population and treatment duration based on the AHEAD3-45 study, and exploring combination therapies. The transition to primary care is seen as particularly significant due to the current bottleneck in accessing neurologists. Eisai aims to simplify the AD treatment pathway with blood-based Aβ testing and subcutaneous administration of Leqembi.

Furthermore, Eisai has updated key metrics in the AD diagnosis and treatment process, anticipating significant progress across Integrated Delivery Networks, neurologists with established pathways, and community practices by the end of the first quarter of 2024. They also provided a revenue simulation for Leqembi, projecting peak worldwide revenues of approximately $10 billion by 2032, with 60% coming from the U.S. market. Oppenheimer's revenue estimate for Biogen's share of Leqembi in 2029 stands at $3.4 billion, higher than the consensus of $2.4 billion.

The report also notes the importance of addressing both major AD pathologies—amyloid plaque and neurofibrillary tangles. Eisai is developing an anti-MTBR tau antibody, E2814, aiming for approval by 2030. Additionally, optimism is expressed for other tau-targeted therapies, including PRTA's PRX012 and the collaborative PRX005 with BMY, as well as Alzheon's oral ALZ-801.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.